A Cell Signaling and Cancer Pathways Researcher is at the forefront of understanding how disruptions in cellular communication lead to cancer. Within every cell, signaling pathways control critical functions like growth, differentiation, and programmed cell death. When these signals are misregulated—due to genetic mutations, environmental triggers, or epigenetic changes—normal cells can transform into cancerous ones. Researchers in this field study key pathways such as MAPK/ERK, PI3K/AKT, JAK/STAT, and Wnt/β-catenin, all of which are commonly altered in various cancer types. Their goal is to map out these pathways in detail, identify the specific molecular aberrations driving malignancy, and uncover how these signals interact and evolve during tumor progression.
By leveraging tools like next-generation sequencing, proteomics, single-cell analysis, and molecular imaging, these researchers provide critical insights into how cancers resist therapy, metastasize, or evade immune detection. Their work is vital for developing targeted cancer therapies—drugs that inhibit specific components of dysregulated signaling pathways—while minimizing damage to healthy cells. Additionally, they often collaborate with clinicians and pharmaceutical companies to translate lab discoveries into clinical treatments. In doing so, Cell Signaling and Cancer Pathways Researchers contribute not only to our understanding of cancer biology but also to the development of more precise, personalized, and effective therapeutic strategies.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China